Company intelligence / Profile preview
Jilin Sihuan Pharmaceutical
Meihekou, Jilin, Chinasihuanpharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Jilin Sihuan Pharmaceutical is a major R&D and manufacturing hub within the Sihuan Pharmaceutical Holdings Group. It focuses on innovative drugs and generics across oncology, metabolic diseases (notably diabetes), cardiovascular/cerebrovascular conditions, and infectious diseases. The company has robust capabilities for both small molecules and biologics with several products at various clinical stages up to Phase 3. Its pipeline includes CDK4/6 inhibitors for cancer as well as insulin analogs and other agents for metabolic disorders.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeMonoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugate
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Jilin Sihuan Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jilin Sihuan Pharmaceutical.